2022 Ljubljana, Slovenia

I-04 Aliénor Bergès
Model informed drug development to accelerate clinical development in life cycle innovation
Wednesday 09:45-11:15
I-06 Mattia Berton
Repository of model parameters for physiologically based pharmacokinetic modelling in obese validated against triazolam and caffeine observed data
Wednesday 09:45-11:15
I-07 Jantine Brussee
Population PK modelling for the iminosugar lucerastat supports dose adaptation in patients with Fabry disease and moderate to severe renal impairment
Wednesday 09:45-11:15
I-08 Laura Bukkems
Relationship between factor VIII activity levels and bleeding for rFVIII-SingleChain in patients with severe hemophilia A
Wednesday 09:45-11:15
I-09 Myriam Chartoire
Investigation of the design of the capsaicin cough challenge test
Wednesday 09:45-11:15
I-12 Vincent Croixmarie
Dose selection and adaptation strategy in renal impaired patients for a phase 2 study with a Clinical Trial Simulation strategy
Wednesday 09:45-11:15
I-13 Anna Dari
Quantifying the Persistence of Immunogenicity After a Single Dose of Ad26.COV2.S in Humans Using a Mechanistic Modeling & Simulation Approach
Wednesday 09:45-11:15
I-15 Alan Faraj
Model-informed dose selection in phase-3 trials for prophylactic treatment with dalcinonacog alfa in adult and pediatric hemophilia B patients
Wednesday 09:45-11:15
I-17 Thomas Frank
Population pharmacokinetic/pharmacodynamic modeling to demonstrate comparability of exposure and activity of insulin aspart Sanofi
Wednesday 09:45-11:15
I-18 Aline Fuchs
The human FcRn transgenic mice Tg32 as a model for early assessment and prediction of human pharmacokinetics of monoclonal antibodies
Wednesday 09:45-11:15
I-23 Chih-hsuan Hsin
Hepatic impairment affects pharmacokinetics and pharmacodynamics of selatogrel, a novel subcutaneous P2Y12 receptor antagonist
Wednesday 09:45-11:15
I-26 Angela Khodzhayev
Esophageal Eosinophil Count and the Endoscopic Reference Score Remodeling Subscore Do Not Correlate in Placebo Treated Eosinophilic Esophagitis Patients: Phase 2 Proof-of-Concept and Phase 3 TREET Studies
Wednesday 09:45-11:15
I-27 Jane Knöchel
Accelerating clinical development of a novel PCSK9 antisense oligonucleotide using semi-mechanistic pharmacodynamic modelling
Wednesday 09:45-11:15
I-29 Olivier Le Tilly
Non-linear pharmacokinetics of eculizumab in atypical haemolytic uremic syndrome
Wednesday 09:45-11:15
I-30 Feiyan Liu
A system pharmacology Boolean network model for the TLR4-mediated host response in early sepsis
Wednesday 09:45-11:15
I-31 Igor Locatelli
A Bayesian mixed treatment comparison meta-analysis of pulmonary arterial hypertension therapies
Wednesday 09:45-11:15
I-37 Joo Young Na
Population pharmacokinetic analysis of omeprazole according to CYP2C19 polymorphism in elderly subjects
Wednesday 09:45-11:15
I-41 Tiffany Pela
Quality of Life and Symptom Burden Among Patients With Eosinophilic Esophagitis in a Real-World Setting
Wednesday 09:45-11:15
I-42 Carlos Perez-Ruixo
Population pharmacokinetic modelling of selexipag and its active metabolite after oral and intravenous administration in adult pulmonary arterial hypertension patients
Wednesday 09:45-11:15
I-43 Christoph Pfaffendorf
Population pharmacokinetic model of atovaquone in infants to adults
Wednesday 09:45-11:15
I-45 Elodie Plan
Bounded integer model-based analysis of psoriasis area and severity index in patients with moderate-to-severe plaque psoriasis receiving BI 730357 treatment
Wednesday 09:45-11:15
I-47 Mar Ribera I Armengol
A perspective on the kinetics of the oral administration of Mirabegron to treat overactive bladder in spinal cord injury patients
Wednesday 09:45-11:15
I-49 Karine Rodriguez-Fernandez
External validation of a population pharmacokinetic model of adalimumab in patients with hidradenitis suppurativa
Wednesday 09:45-11:15
I-50 Viktor Rognås
An integrated semi-mechanistic model to predict the outcome of drug-target effects on the erythropoietic system
Wednesday 09:45-11:15
I-52 Marina Savelieva
Pharmacometrics and Integrated Evidence Generation: example of ligelizumab in Chronic Spontaneous Urticaria
Wednesday 09:45-11:15
I-53 Daniel Seeler
Towards a qualitative systems biology model to study the effect of blood flow responsive CCM and NO signaling on endothelial cell morphology
Wednesday 09:45-11:15
I-54 Sejung Hwang
Population pharmacokinetic analysis to investigate the effect of ethnicity for extrapolating data from Caucasians to Koreans in eslicarbazepine acetate therapy
Wednesday 09:45-11:15
I-55 Alexander Solms
Reduced FXI levels do not appear to increase bleeding risk in End-Stage Kidney Disease patients - results from an exploratory PK/PD and ER analysis of FXI-ASO
Wednesday 09:45-11:15
I-56 Gilles Tiraboschi
Population Pharmacokinetic and Pharmacodynamic Analyses of Olipudase alfa in Adult and Pediatric Patients with the rare Acid Sphingomyelinase Deficiency (Niemann-Pick) lysosomal storage disease
Wednesday 09:45-11:15
I-57 Thi Quyen Tran
Population pharmacokinetics of a truncated milk fat globule-EGF factor 8 (NP-011) for optimal dose prediction on liver fibrosis
Wednesday 09:45-11:15
I-61 Paul van den Berg
Finerenone Dose-Exposure-Response for the Primary Kidney Outcome in FIDELIO-DKD Phase III: Population Pharmacokinetic and Time-to-Event Analysis
Wednesday 09:45-11:15
I-64 Zhigang Wang
Higher clearance of therapeutic antibodies is associated with worse endoscopic outcomes in patients with Crohn’s disease
Wednesday 09:45-11:15